RMDRMD
US • —
$194.88
P/E
18.79
PEG
1.14
FCF Yield
—
Rev Growth YoY
+10.3% YoY
Gross Margin
61.6%
Health Score
8/10
D/E Ratio
0.11
Confidence
LOW
Business Snapshot
ResMed (RMD) is a leading medical device company focused on cloud-connected solutions for sleep apnea and respiratory care within the healthcare technology sector. The company is best known for its continuous positive airway pressure (CPAP) masks and devices, along with its connected digital health platform that tracks therapy adherence. It operates as a dominant player in the sleep-disordered breathing market, benefiting from a large installed base of patients and a strong brand presence among clinicians. The company generates high-margin revenue through consumable masks and durable device sales, with its recurring revenue stream from consumables providing a visible and stable business foundation.
Financial Health
Gross margins are strong at 61.6%, while net margins (TTM) of 27.4% indicate excellent profitability after all expenses. The balance sheet is conservative and healthy, with a debt-to-equity ratio of just 0.11x and a current ratio of 3.44x, implying ample liquidity and very low financial leverage...
Risk Assessment
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- INSIDER ACTIVITY — 3 insider sells versus 0 buys over the last 90 days represent a net selling trend that warrants monitoring.
- EARNINGS QUALITY — The company beat estimates in only 3 of the last 4 quarters, leaving one miss that is a minor but notable credibility flag.
- DATA COMPLETENESS — Several core fundamental metrics including market capitalisation and TTM revenue are missing, which limits the depth of a comprehensive financial assessment....
Gross margins are strong at 61.6%, while net margins (TTM) of 27.4% indicate excellent profitability after all expenses. The balance sheet is conservative and healthy, with a debt-to-equity ratio of just 0.11x and a current ratio of 3.44x, implying ample liquidity and very low financial leverage. Return on equity is robust at 24.4%, highlighting efficient capital allocation and strong shareholder value creation. Overall financial health is solid, providing the company with significant capacity for reinvestment into R&D, potential acquisitions, or returning capital to shareholders.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - INSIDER ACTIVITY — 3 insider sells versus 0 buys over the last 90 days represent a net selling trend that warrants monitoring. - EARNINGS QUALITY — The company beat estimates in only 3 of the last 4 quarters, leaving one miss that is a minor but notable credibility flag. - DATA COMPLETENESS — Several core fundamental metrics including market capitalisation and TTM revenue are missing, which limits the depth of a comprehensive financial assessment.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives